# A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

> **NCT01809327** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 1186 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 300 mg
- **DRUG:** Metformin XR

## Key facts

- **NCT ID:** NCT01809327
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-04
- **Primary completion:** 2014-12-02
- **Final completion:** 2014-12-02
- **Target enrollment:** 1186 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01809327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01809327, "A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01809327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*